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n today’s research environment, productive collaborations, either local, regional, 
or global, are essential for maximizing the impact of research efforts. This 
sentiment is especially true in many areas of neuroscience, one of the most 
rapidly advancing scientific fields. Given the inherent complexity of the central 
nervous system and the analytical advances that are currently being made in order to 
resolve these intricacies, it is becoming increasingly difficult to maintain of clear 
grasp of all of the relevant neuroscience concepts and also develop and employ 
cutting edge technologies important for investigating these concepts. Thus, it is, 
perhaps, more important than ever for neuroscientists and analytical scientists to 
establish symbiotic collaborations that will enhance the importance of the research. In 
this paper, I discuss ongoing research in my laboratory in which we applied sensitive 
measurement techniques, both in vivo and ex vivo, in order to gain a more complete 
understanding of Huntington’s disease. An important aspect of this discussion is that 
productive collaborations have been a positive force in enhancing our ability to 
resolve some of the underlying neurochemical mechanisms of this disorder.
Modeling Huntington’s disease in 
rodents 
Huntington’s disease is a fatal, genetic 
neurological disorder caused by an 
expansion of CAG repeats on the gene 
encoding huntington (Htt), resulting in an 
expanded chain of glutamine residues at the 
N-terminus of the expressed protein 
(Huntington’s Disease Collaborative 
Research Group, 1993). A sequence of 40 or 
more CAG repeats results in 100 percent 
disease penetrance. Moreover, there is a 
direct correlation between increasing repeat 
number and decreasing age of onset. HD 
results in a debilitating behavioral syndrome 
that includes both psychological and motor 
disturbances. The hallmark motor feature of 
HD is chorea, defined recently as “random, 
abrupt movements superimposed over 
purposeful acts” (Bates et al. 2002). 
The discovery of the HD mutation in 
1993 by the Huntington’s disease 
collaborative research group opened the way 
for the development of genetically-
engineered animals that model the 
neurological and motor phenotype of human 
HD. The R6 line of transgenic mice was 
developed in 1996 (Mangiarini et al. 1996) 
and represents the first genetic rodent model 
of HD. Within this line the R6/2 mouse, 
which possess the gene required for the 
expression of exon I of the human Htt protein 
I 
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with a CAG repeat length of about 150, is 
among the most used HD model rodents. 
This strain develops a motor syndrome at 9 
to 11 weeks of age that roughly approximates 
HD in humans. Since the development of the 
R6 line, many other mouse lines have been 
developed, including knock-in and full-
length, that are thought by many to more 
faithfully replicate the neurological 
phenotype of HD (reviewed in Levine et al. 
2004 and Menelled 2005). Additionally, a 
transgenic HD (HDtg) rat strain that 
possesses a fragment of the human HD gene 
with 51 CAG repeats has been developed 
(von Hörsten et al. 2003). Although the HDtg 
rat possesses a mutation similar to that of the 
R6/2 mouse, it has the advantage of 
developing the disease syndrome over a 
longer period of time (20-24 months 
compared to 9-11 weeks), providing a richer 
array of behavioral abnormalities over the life 
span of the animal. Additionally, the larger 
size of the HDtg rat facilitates the conduction 
more intricate neurochemical and behavioral 
experiments, including those that involve in 
vivo microdialysis and fast-scan cyclic 
voltammetry measurements. 
Our collaborative approach toward 
studying CNS function 
Broadly stated, the mission of our 
laboratory is to develop and apply analytical 
methods for the study of biological systems. 
Current methods that we employ include 
fast-scan cyclic voltammetry at carbon-fiber 
microelectrodes, microdialysis sampling, and 
fluorescence microscopy. We currently use 
these methods to measure dopamine release 
and uptake in rodents that model HD, 
including R6/2 mice and HDtg rats. We 
obtained breeding pairs of these rats through 
a collaboration with Prof. Stephan von 
Hörsten, Erlangen University, Germany, and 
Prof. Olaf Riess, Tubingen University, 
Germany. Another important aspect of this 
project is the measurement of behavior. For 
these studies we are collaborating with Prof. 
Stephen C. Fowler, Department of 
Pharmacology and Toxicology, University of 
Kansas, in order to measure behaviors at 
millisecond timescales, and also to correlate 
these behaviors with millisecond timescale 
voltammetric measurements. Finally, we 
have entered into a collaboration with Dr. 
Dave Johnson and Donna Johnson, Pinnacle 
Technology Inc., Lawrence, KS, to develop a 
wireless fast-scan cyclic voltammetry system. 
This technology will enable us to obtain 
voltammetric measurements in the context of 
behavioral paradigms of increasing 
complexity. All of these collaborations have 
been invaluable in strengthening our 
experimental approaches by expanding our 
repertoire of capabilities. For example, we 
have been able to directly correlate 
neurochemical signaling events with 
behaviors in rats by obtaining our fast-scan 
cyclic voltammetry measurements 
simultaneously with behavioral 
measurements collected using a force-plate 
actometer, developed by S.C. Fowler. 
Reserve pool measurements in R6/2 
mice 
Recent evidence, much of it collected by 
our laboratory, show that vesicular 
dopamine release is impaired in the striata of 
multiple types of HD model rodents. 
Previous results have indicated that 
dopamine release is impaired in R6/2 mice 
compared to WT control mice. Moreover, our 
data suggest that reserve pool dopamine, 
which is available for periods of extended 
synaptic activity, is depleted in R6/2 mice. 
Therefore, we sought to assess how well 
dopamine reserve pool vesicles are 
mobilized. It has been shown recently that 
cocaine, a powerful psychostimulant that 
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impairs dopamine uptake by competitively 
inhibiting the dopamine transporter, also 
increases dopamine release in mice by 
mobilizing a synapsin-dependent dopamine 
reserve pool (Venton et al., 2006). Therefore, 
we used cocaine as a tool to mobilize 
dopamine reserve pools in striatal brain slices 
from R6/2 and WT mice (Fig. 1). This 
experiment was carried out by treating brain 
slices with αMPT, which blocks dopamine 
synthesis, while providing a single electrical 
stimulus pulse every 5 minutes to deplete 
releasable vesicles of dopamine. Dopamine 
release and uptake were measured using 
FSCV. After dopamine release disappeared 
during treatment with αMPT, cocaine was 
applied to the brain slice, in addition to both 
αMPT treatment and the ongoing application 
of the stimulus pulses. In both R6/2 and WT 
brain slices, dopamine release almost 
immediately reappeared and increased to 
about 20% of pre-drug release, presumably 
due to the mobilization of vesicular reserve 
pools. However, dopamine release from R6/2 
brain slices disappeared more quickly than 
WT (~35 min versus ~105 min). Therefore, 
these data support a scenario in which 
vesicles from both R6/2 and WT slices are 
mobilized effectively; however, it appears 
that there are less reserve pool vesicles 
available for mobilization in R6/2 slices. 
Behavioral and neurochemical 
measurements in HDtg rats 
A synchronized behavioral 
/neurochemical approach was employed in 
which microdialysis sampling was used to 
measure trends in extracellular dopamine 
levels while behavior was simultaneously 
measured at 100 samples/s using the force 
plate actometer (Fig. 2). Male hmHDtg rats 
and male WT control rats, 9 months old, 
were injected with AMPH (5.0 mg/kg, i.p.) 
and behavior was measured in the actometer 
for 240 minutes (Fig. 2A). During this time, 
microdialysis samples were collected from 
the dorsal lateral striatum every 15 minutes. 
Dialysates were subsequently analyzed for 
dopamine concentration using high 
performance liquid chromatography with 
electrochemical detection. Our results show 
that, after injection with AMPH, extracellular 
dopamine levels increased dramatically and 
then decreased gradually in both hmHDtg 
and WT rats (Fig. 2B). During this increase in 
extracellular dopamine levels, the space used 
in the actometer, which serves as a measure 
of focused stereotypy spatial confinement, 
also was initially elevated. WT rats used 
significantly less space (more stereotypy) 
compared to hmHDtg rats 30 to 135 minutes 
after AMPH injection despite the fact that 
there was not a difference in extracellular 
dopamine levels during this time or 
throughout the entire 240-minute 
measurement period. Therefore, hmHDtg 
rats appear to be resistant to AMPH-induced 
spatial confinement and focused stereotypy, 
while the WT control rats are not. 
Additionally, there was no difference in pre-
injection dopamine levels or in dopamine 
levels after injection with saline vehicle (data 
not shown). Consequently, this experiment is 
important because it suggests that differences 
in psychostimulant-induced behavior 
between HDtg and WT rats do not result 
from differences in basal extracellular 
dopamine levels aggregated across 15 min. 
Thus, we propose an alternate mechanism: 
behavioral differences between genotypes 
arise from differences in the characteristics, 
such as frequency of occurrence, of 
dopamine transients, which cannot be 
detected by microdialysis. Our experimental 
approach, therefore, was to use FSCV to 
measure striatal dopamine release transients 
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in ambulatory HDtg rats and WT control 
rats.  
Dopamine transient frequency of 
occurrence in HDtg rats 
We quantified the frequency of 
occurrence of dopamine release transients in 
hmHDtg rats and WT control rats (n = 3 
hmHDtg and 3 WT; age = 12 months). 
Shown in Fig. 3 are representative data taken 
from a 12-month old hmHDtg rat and a 12-
month old WT littermate control rat. The 
release plots (center trace of each picture) for 
the WT and hmHDtg rats are expressed here 
in terms of current and show the occurrence 
of dopamine transients measured at a 
sampling rate of 10 cycles/s. A CV, 
corresponding to the peak marked with an 
asterisk, is shown above the trace and 
confirms the presence of dopamine. Color 
plots, constructed by unhinging sequential 
CVs, stacking them from left to right, and 
expressing current as color, are also shown. 
For a given rat, files collected 15 to 21 minutes 
after attaching the rat to the voltammetry 
system were analyzed (six 1-minute files per 
rat). Peaks that represent dopamine 
transients were identified by inspection of the 
respective CVs. The frequency of transients 
was calculated by averaging the number of 
transients identified by the number of 
minutes of measurement. The analysis of the 
data yielded an average of 7.2 ± 2.3 
transients/min occurring in the hmHDtg rats 
and an average of 2.6 ± 0.6 transients/min 
occurring in the WT rats (p = 0.084, t-test). For 
these analyses, each group consisted of two 
male rats and one female rat. It is interesting 
to note that the female rats of both genotypes 
had a dopamine transient frequency roughly 
half that of the respective male rats. The 
recent paper by Bode et al. (2008) revealed sex 
differences present in the HD rats, and the 
differences seen between male and female 
rats in our studies may be reflective of these 
findings. Overall, these data are significant 
because they suggest that HDtg rats may 
release dopamine transients at a greater 
frequency than WT control rats. These 
increased dopamine signaling events may, 
therefore, impact MSN neuron firing 
properties, discussed in the following sub-
section.  
Simultaneous collection of behavioral 
and neurochemical data in rats  
Collecting neurochemical and 
behavioral measurements separately allows 
for behavioral and neurochemical 
comparisons to be made between age groups 
and drug treatments. Nevertheless, 
simultaneous data collection will, due to the 
close temporal association of the data, allow 
for even more direct comparisons between 
behavior and neurochemistry. Additionally, 
this method also maximizes the use of each 
rat. To demonstrate feasibility, voltammetry 
data were collected from a normal male 
Sprague-Dawley rat behaving on a force 
plate actometer (Fig. 4). FSCV and actometer 
measurements were electronically 
synchronized. The rat received an ip (5 
mg/kg) injection of AMPH 60 minutes after 
the start of data collection. As can be seen 
from these data, during the last ~24 min, the 
rat developed focused stereotypy, indicated 
by the presence of a 10 Hz Z-axis force peak 
(“Power Spectra”; behavioral data at top of 
Fig. 4) and by the lack of X-Y movement on 
the force plate (“Track”). Moreover, naturally 
occurring dopamine release transients, 
measured soon after injection, and a longer 
series of transients, measured 16 minutes 
after injection, are shown. These data 
demonstrate the feasibility of simultaneously 
measuring naturally-occurring dopamine 
transients and behavioral alterations at near-
millisecond temporal resolutions.  
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Concluding remarks 
The data presented here are made 
available not only by the hard work of 
personnel in the Johnson laboratory, but also 
are the product of important collaborations 
that have been established. These 
collaborations were necessary to obtain the 
transgenic HDtg rats (S. von Hörsten and O. 
Riess, Germany) and also to obtain 
behavioral measurements (S.C. Fowler). 
These types of complimentary efforts are 
expected to become increasingly important 
for neuroscience research as newer, more 
specialized techniques are developed.  
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Figure 1. Cocaine-mobilized reserve pools are 
diminished in R6/2 mice compared to WT mice. Brain 
slices from 12-week old R6/2 mice and age-matched WT 
control mice were treated with α-methyl-p-tyrosine (50 
µM). When stimulated dopamine release disappeared, 
cocaine (20 µM) was also added to the perfusion 
solution. The peak cocaine-induced increase in 
stimulated dopamine release in R6/2 slices was not 
significantly less than that observed in WT slices, but 
was substantially shorter in duration (n = 5 WT and 5 
R6/2 mice). 
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Fig. 2. Transgenic HD rats are less spatially confined than 
WT rats after AMPH injection even though extracellular 
dopamine levels are the same. Rats were injected i.p. (5.0 
mg/kg) with AMPH at t = 0 min and synchronized behavioral and 
neurochemical measurements were collected. A, Space used (y-
axis) was measured using the force plate actometer. The 
asterisked bar denotes 15-min time blocks in which the space 
used was significantly different between WT and hmHDtg rats (p 
< 0.01). Force spectra (arbitrary units), derived from Fourier 
analyses, are shown below respective plots of Space Used. WT 
rats develop classic 8 to 10 Hz focused stereotypy, while hmHDtg 
rats express an altered force response at lower frequencies. 
Force is normalized to body weight for all force spectra. B, Plot of 
average (± SEM) extracellular dopamine levels obtained by 
microdialysis sampling conducted simultaneously with the force 
plate actometer measurements. Values are normalized against 
the same rats injected with saline three days prior. Samples were 
collected from 4 HDtg rats and 5 WT rats while behavior was 
simultaneously measured using the force-plate actometer. 
Therefore, the behavioral data directly correspond to the force 
spectra plots collected within 15 minute time periods between 
adjacent pairs of data points.  
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Figure 3.  Alterations in dopamine release transients measured from HDtg 
rats.  FSCV was used to measure transient spikes in extracellular dopamine 
concentration in the dorsolateral caudate of male WT and hmHDtg rats.  The 
release plots of dopamine transients are shown above the color plots.  Current 
was sampled at about +0.6 V for each successive CV.  A sample CV 
corresponding to one of the peaks, denoted by an asterisk, confirms the presence 
of dopamine.  Corresponding color plots of successive CVs, unhinged and 
stacked, are shown below the release plots.  Different currents are expressed as 
different colors (scale shown on right side of plot).  The time scale bar on the color 
plot also applies to the release plot.  Scan rate:  400 V/s, CV update rate:  10 
CVs/s.       
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Fig. 4.  Simultaneous, near-millisecond measurements of 
dopamine release transients and behavior.  A male 
Sprague-Dawley rat (weight 500 g) was injected i.p. (5 mg/kg) 
with AMPH (indicated by arrow) 60 min after initiation of 
behavioral and voltammetric measurements.  The collection 
of actometer data, including space used, stereotypy score, 
power spectra, X-Y track, and number of rotations (top panel) 
was synchronized with the collection of voltammetry files 
(bottom color plots and CVs).  Behavioral data, collected at 
100 samples/s, was synchronized to the nearest ms with the 
voltammetry data, collected at 10 CVs/s.  The CVs were 
sampled from the color plots at the white vertical lines.  
Voltammetry data sampling ranges are shown beneath the 
respective color plots.      
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he National Center for Research Resources (NCRR) at the National Institutes 
of Health has developed the Institutional Development Award (IDeA) 
program to enhance biomedical research where NIH funding has been in the 
lower tier. Twenty-three states and Puerto Rico qualify for IDeA programs, including 
Nebraska, Kansas, and Oklahoma in our region. The Centers for Biomedical Research 
Excellence (COBRE) program is one of these mechanisms. COBREs are each 
organized around a central scientific theme, and the growth of research in that area is 
facilitated in three ways: support of core facilities to serve as resources, support of 
individual research projects primarily for junior faculty, and development of a 
mentoring program to ensure that the research projects result in independent NIH 
funding. In addition to building a network of successful researchers within a COBRE, 
regional interaction of COBREs and other IDeA programs is encouraged.
In building the research 
infrastructure of a state, a COBRE 
program has a particularly unique 
aspect: the research projects associated 
with the center are generally junior 
investigators who have not had previous 
renewable NIH funding, and their 
projects are designed to be the basis of 
grant applications that are funded after 2 
-3 years of Center support. When 
external funding starts, the projects 
rotate off Center funding and new 
projects take their place. The mentoring 
program provides advice to the 
investigators to help ensure that he 
projects are successful, and the core 
facilities provide technical support for 
the investigators as well as for other 
researchers in the participating 
institutions. Thus, the Center can aid 
junior faculty in establishing an 
independent research program, and can 
also help make advanced technologies 
available to researchers beyond the 
Center. 
The Nebraska Center for the 
Molecular Biology of Neurosensory 
Systems is built around the 
characterization of the molecular 
mechanisms controlling the 
development and maintenance of 
neurosensory functions, particularly 
vision and hearing. Neurosensory cells 
of the inner ear and retina are not 
replaced after damage or degeneration, 
so understanding of the regulation of 
T 
